Miscellaneous Immune Disorders

Firdapse NDA Submitted for Lambert-Eaton Myasthenic Syndrome

By April 02, 2018

Results from the Phase 3 trial showed that the Quantitative Myasthenia Gravis (QMG) score at baseline to day 14 changed from 6.4 to 6.7 in the amifampridine group vs. 5.6 to 7.9 for the placebo group.

Hizentra Approved for Chronic Inflammatory Demyelinating Polyneuropathy

By March 16, 2018

The PATH study demonstrated that the percentage of patients experiencing CIDP relapse or withdrawal for any other reason during SCIg treatment was significantly lower with Hizentra

Rituxan Granted Priority Review for Rare Autoimmune Disease

By February 16, 2018

The disease can be life threatening. Phase 3 study results released last March demonstrated Rituxan substantialy improved pemphigus vulgaris remission rates and successful tapering.

Are Patients With ITP at Increased Risk for Cardiovascular Disease?

January 09, 2018

The elevated risk of developing CVD in the ITP cohort (adjusted incidence rate ratio [IRR], 1.38) remained even after a sensitivity analysis which included only incident cases of ITP.

Autologous stem-cell transplantation improves survival in scleroderma patients: The SCOT trial

January 05, 2018

Scleroderma patients treated with myeloablative autologous stem-cell transplantation experienced significantly higher rates of disease-free survival at 52 months post-treatment compared to those treated with cyclophosphamide.

Rituximab Effective for Lupus-Associated Cytopenia

December 27, 2017

Overall initial response rate of 86% in 71 patients, with complete response for 60.5%

Nucala Approved to Treat Rare Autoimmune Disease That Causes Vasculitis

By December 12, 2017

EGPA (formerly known as Churg-Strauss syndrome) is a condition characterized by asthma, high levels of eosinophils (a type of white blood cell that helps fight infection), and inflammation of small- to medium-sized blood vessels.

Newly Approved Prophylaxis Assessed in CMS-Seropositive Transplant Recipients

December 08, 2017

The researchers found that among 495 patients with undetectable CMV DNA at randomization, fewer patients in the letermovir group had clinically significant CMV infection or were classified as having a primary end point event by week 24 after transplantation, compared with the placebo group.

Prevymis Approved for Prevention of Cytomegalovirus Infection and Disease

By November 09, 2017

Prevymis, a non-nucleoside CMV inhibitor (3,4 dihydro-quinazoline), inhibits viral replication through targeting the viral terminase complex.

What Are the Clinical Characteristics of Hepatic Sarcoidosis?

By September 18, 2017

Most patients were asymptomatic and the diagnosis was discovered in pursuit of other abnormal biochemical tests and imaging studies. In the majority of patients, alkaline phosphatase (ALP) and gamma-glutamyl transferase (GGT) were elevated (88 and 90%, respectively).

Privigen Approved for Chronic Inflammatory Demyelinating Polyneuropathy

By September 15, 2017

The FDA approval was based on data from two Phase 3 studies, PATH and PRIMA.

Benlysta FDA-Approved as New Self-Injectable Formulation

By July 21, 2017

The FDA approval was supported by data from the BLISS-SC Phase 3 study (n>800) in patients with active SLE.

Giant Cell Arteritis Treatment Gets FDA Approval

By May 22, 2017

In the study, Actemra given weekly and bi-weekly combined with a 6-month glucocorticoid regimen, more effectively sustained remission through Week 52 than placebo combined with a 26-week steroid taper and a 52-week steroid taper.

Plant Found to Harbor Drug-Resistant Fungal Pathogen

By May 18, 2017

Results showed that 5 of the 6 bulb packages tested positive for triazole-resistant A. fumigatus.

Progress Made in Possible First Treatment for Lymphedema

May 11, 2017

Based on the lab findings, a clinical trial testing bestatin against lymphedema is underway, Dr. Stanley Rockson lead author of the research.

Updated Review of Discoid Lupus Erythematosus Treatments

By May 09, 2017

For each of the five studies, researchers found a potential for bias through conducting a 'Risk of bias' assessment; none of the trials were deemed 'high quality'

Insulin Autoimmune Syndrome Treated with Rituximab

May 05, 2017

Following treatment with rituximab, decreases seen in total insulin, anti-insulin antibody concentration

Powder Form of Ilaris Permanently Discontinued

By April 28, 2017

Ilaris for Injection will be replaced by Ilaris Injection (solution) for subcutaneous use.

Tissue-Based Tx Granted Breakthrough Status for Complete DiGeorge Syndrome

By April 19, 2017

The FDA has granted Breakthrough Therapy and Regenerative Medicine Advanced Therapy (RMAT) designations for the investigational tissue-based therapy, RVT-802 (Enzyvant), for the treatment of complete DiGeorge Syndrome (cDGS).

FDA to Review Fostamatinib for Chronic, Persistent ITP

By April 18, 2017

Rigel announced its submission of a New Drug Application (NDA) to the Food and Drug Administration (FDA) for fostamatinib for the treatment of patients with chronic and persistent immune thrombocytopenic purpura (ITP).

Novel Budesonide Prep May Treat Rare GI Disorder

March 28, 2017

A trial involving 93 eosinophilic esophagitis patients aged 11 to 40 years with dysphagia were randomly allocated to receive either budesonide oral suspension or placebo twice daily.

Rituxan Gets Breakthrough Therapy Status for Rare Autoimmune Skin Disorder

By March 24, 2017

Genentech announced that the Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to Rituxan (rituximab) for the treatment of pemphigus vulgaris.

Holy Basil: Health Benefits of 'The Elixir of Life'

February 22, 2017

Holy basil is not recommended for pregnant or nursing mothers or young children. It should also be used with caution in patients with diabetes.

Psoriasis Treatment Linked to Drug-Induced Lupus Erythematosus

February 21, 2017

Patient with psoriasis developed muscle pain with paresthesia, ANA titer elevation with adalimumab

Tocilizumab Gets Priority Review for Treatment of Giant Cell Arteritis

By January 24, 2017

Genentech has announced that the Food and Drug Administration (FDA) has accepted the company's Supplmental New Drug Application (sBLA) for Actemra (tocilizumab) to treat giant cell arteritis (GCA).

Islet Autoimmunity Measured With Non- and Hydrolyzed Cow's Milk

January 20, 2017

Use of hydrolyzed cow's milk-based formula introduced during the first seven days is associated with increased risk of islet autoimmunity in infants at increased risk of type 1 diabetes (T1D), according to a study published online in Diabetes Care.

Just 20 Minutes of Exercise Shows Surprising Benefits

January 19, 2017

Just 20 minutes of moderate exercise may reduce inflammation in the body, according to research published online recently in Brain, Behavior, and Immunity.

Masitinib Examined in Severely Symptomatic Indolent Systemic Mastocytosis

By January 06, 2017

Lortholary, O, Chandesris, MO, Livideanu CB, et al. "Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study."

Sustained Disease Control Seen With Long-Term Belimumab in SLE

By November 16, 2016

Long-term safety and efficacy data from a continuation study of Benlysta in patients with systemic lupus erythematosus (SLE) has been released.

Tocilizumab Superior to Steroids Alone for Giant Cell Arteritis Remission

By November 15, 2016

Positive data was presented for Actemra (tocilizumab) therapy in patients with giant cell arteritis (GCA).